Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LINDE PLCLIN · Entity 2835 | Principal Accounting Officer | March 09, 2026 | March 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LINDE PLC
Report date March 09, 2026 · Filed March 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,050.191 |
Ending reported balance
After 2026-03-09 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-03-09 · Exercise / conversion · Acquired 907 · Balance 21,937.191 F1: Ordinary shares acquired pursuant to the payout of a performance share unit ("PSU") grant made on March 7, 2023. Row 2 · 2026-03-09 · Tax withholding · Disposed 285 · Balance 21,652.191 F2: Ordinary shares withheld from the payout to cover tax withholdings. Row 3 · 2026-03-09 · Exercise / conversion · Acquired 320 · Balance 21,972.191 F1: Ordinary shares acquired pursuant to the payout of a performance share unit ("PSU") grant made on March 7, 2023. Row 4 · 2026-03-09 · Tax withholding · Disposed 101 · Balance 21,871.191 F2: Ordinary shares withheld from the payout to cover tax withholdings. Row 5 · 2026-03-09 · Exercise / conversion · Acquired 320 · Balance 22,191.191 F3: Ordinary shares acquired pursuant to the payout of a restricted stock unit grant made on March 7, 2023. Row 6 · 2026-03-09 · Tax withholding · Disposed 141 · Balance 22,050.191 F2: Ordinary shares withheld from the payout to cover tax withholdings. |
| Performance Share Units (RTSR)SEC Table II · derivative / convertible security | Direct | 907 |
Reported balance
After 2026-03-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-03-09 · Grant · Acquired 907 · Balance 907 F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis. F5: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the relative total shareholder return ("RTSR") of Linde plc from 2023-2025 measured against TSR goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023. |
| Performance Share Units (RTSR)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-03-09 · Exercise / conversion · Disposed 907 · Balance 0 F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis. F5: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the relative total shareholder return ("RTSR") of Linde plc from 2023-2025 measured against TSR goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023. |
| Performance Share Units (ROC)SEC Table II · derivative / convertible security | Direct | 320 |
Reported balance
After 2026-03-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-03-09 · Grant · Acquired 320 · Balance 320 F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis. F6: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the average annual return on capital ("ROC") of Linde plc from 2023-2025 measured against ROC goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023. |
| Performance Share Units (ROC)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-09 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-09 · Exercise / conversion · Disposed 320 · Balance 0 F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis. F6: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the average annual return on capital ("ROC") of Linde plc from 2023-2025 measured against ROC goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 293 |
Reported balance
After 2026-03-09 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-03-09 · Grant · Acquired 293 · Balance 293 F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis. F7: Restricted Stock Units that will vest in full and payout on or about March 9, 2029 in Linde plc Ordinary Shares on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-09 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-03-09 · Exercise / conversion · Disposed 320 · Balance 0 F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis. F11: Restricted Stock Units that vested in full and paid out on March 9, 2026 in Linde plc Ordinary Shares on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 265 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 265 F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis. F8: Restricted Stock Units that will vest in full and payout on or about March 7, 2027 in Linde plc Ordinary Shares on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 155 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 155 F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis. F9: Restricted Stock Units that will vest in full and payout on or about May 1, 2027 in Linde plc Ordinary Shares on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 288 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 288 F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis. F10: Restricted Stock Units that will vest in full and payout on or about March 7, 2028 in Linde plc Ordinary Shares on a one-for-one basis. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $483.62 · Expires 2036-03-09 | Direct | 2,387 |
Reported balance
After 2026-03-09 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-03-09 · Grant · Acquired 2,387 · Balance 2,387 F12: This option vests over three years in three consecutive equal annual installments beginning on March 9, 2027. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $468.77 · Expires 2035-03-07 | Direct | 2,017 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 2,017 F13: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2026. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $465.29 · Expires 2034-03-07 | Direct | 1,720 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · Balance 1,720 F14: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2025. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $354.14 · Expires 2033-03-07 | Direct | 2,110 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · Balance 2,110 F15: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2024. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $270.99 · Expires 2032-03-07 | Direct | 2,680 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · Balance 2,680 F16: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2023. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $253.68 · Expires 2031-03-08 | Direct | 4,100 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · Balance 4,100 F17: This option vests over three years in three consecutive equal annual installments beginning on March 8, 2022. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $173.13 · Expires 2030-03-09 | Direct | 5,545 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · Balance 5,545 F18: This option vests over three years in three consecutive equal annual installments beginning on March 9, 2021. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $176.63 · Expires 2029-03-20 | Direct | 5,995 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · Balance 5,995 F19: This option vests over three years in three consecutive equal annual installments beginning on March 20, 2020. |
| Ordinary SharesSEC Table I · non-derivative | Indirect401(k) | 567.573 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 567.573 |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 180.368 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · Balance 180.368 F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis. F20: Deferred stock units acquired under the Compensation Deferred Plan as amended ("Plan"). The deferred stock units will payout in Linde plc Ordinary Shares on a one-for-one basis in accordance with the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary shares acquired pursuant to the payout of a performance share unit ("PSU") grant made on March 7, 2023.
F2: Ordinary shares withheld from the payout to cover tax withholdings.
F3: Ordinary shares acquired pursuant to the payout of a restricted stock unit grant made on March 7, 2023.
F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis.
F5: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the relative total shareholder return ("RTSR") of Linde plc from 2023-2025 measured against TSR goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023.
F6: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the average annual return on capital ("ROC") of Linde plc from 2023-2025 measured against ROC goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023.
F7: Restricted Stock Units that will vest in full and payout on or about March 9, 2029 in Linde plc Ordinary Shares on a one-for-one basis.
F8: Restricted Stock Units that will vest in full and payout on or about March 7, 2027 in Linde plc Ordinary Shares on a one-for-one basis.
F9: Restricted Stock Units that will vest in full and payout on or about May 1, 2027 in Linde plc Ordinary Shares on a one-for-one basis.
F10: Restricted Stock Units that will vest in full and payout on or about March 7, 2028 in Linde plc Ordinary Shares on a one-for-one basis.
F11: Restricted Stock Units that vested in full and paid out on March 9, 2026 in Linde plc Ordinary Shares on a one-for-one basis.
F12: This option vests over three years in three consecutive equal annual installments beginning on March 9, 2027.
F13: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2026.
F14: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2025.
F15: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2024.
F16: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2023.
F17: This option vests over three years in three consecutive equal annual installments beginning on March 8, 2022.
F18: This option vests over three years in three consecutive equal annual installments beginning on March 9, 2021.
F19: This option vests over three years in three consecutive equal annual installments beginning on March 20, 2020.
F20: Deferred stock units acquired under the Compensation Deferred Plan as amended ("Plan"). The deferred stock units will payout in Linde plc Ordinary Shares on a one-for-one basis in accordance with the Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PRAXAIR INC
Report date October 31, 2018 · Filed November 01, 2018
Section 16 reporting ended · disclosed 2018-11-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirect401(k) | 0 |
Reported balance
After 2018-10-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-10-31 · Disposition to issuer · Disposed 452.9426 · Balance 0 F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. |
| Common stockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 2
1 source rowRow 2 · 2018-10-31 · Disposition to issuer · Disposed 1,850.563 · Balance 0 F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-10-31 · Disposition to issuer · Disposed 1,165 · Balance 0 F2: Restricted Stock Units ("RSUs") that were previously awarded by Praxair, Inc. will vest 100% on February 27, 2021. In connection with the BCA, the RSUs have been converted into RSUs of Linde plc Ordinary Shares on a one-for-one basis. F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-10-31 · Disposition to issuer · Disposed 666 · Balance 0 F3: Restricted Stock Units previously awarded by Praxair on February 23, 2016 that will vest and payout on February 23, 2019. In connection with the BCA, the RSUs were converted to RSUs of Linde plc Ordinary Shares on a one-for-one basis. F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-10-31 · Disposition to issuer · Disposed 1,152 · Balance 0 F4: Restricted Stock Units previously awarded by Praxair, Inc. on February 28, 2017 that will vest and payout on February 28, 2020. In connection with the BCA, the RSUs were converted to RSUs of Linde plc Ordinary Shares on a one-for-one basis. F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-10-31 · Disposition to issuer · Disposed 682 · Balance 0 F3: Restricted Stock Units previously awarded by Praxair on February 23, 2016 that will vest and payout on February 23, 2019. In connection with the BCA, the RSUs were converted to RSUs of Linde plc Ordinary Shares on a one-for-one basis. F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-10-31 · Disposition to issuer · Disposed 790 · Balance 0 F4: Restricted Stock Units previously awarded by Praxair, Inc. on February 28, 2017 that will vest and payout on February 28, 2020. In connection with the BCA, the RSUs were converted to RSUs of Linde plc Ordinary Shares on a one-for-one basis. F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $109.68 · Expires 2022-02-28 | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-10-31 · Disposition to issuer · Disposed 3,995 · Balance 0 F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. F5: This option became exercisable in three (3) equal annual installments beginning on the first anniversary of the date of grant. and was fully vested and exercisable. In accordance with the Business Combination Agreement, each stock option of Praxair outstanding immediately prior to the effective date of the Business Combination (whether vested or unvested) was automatically converted into an option to purchase shares of Linde plc ordinary shares equal to the total number of shares of Praxair Common Stock subject to such option immediately prior to the closing of the Business Combination and at a per-share exercise price equal to the per-share exercise price of Praxair's option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $110.58 · Expires 2023-02-26 | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-10-31 · Disposition to issuer · Disposed 2,675 · Balance 0 F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. F5: This option became exercisable in three (3) equal annual installments beginning on the first anniversary of the date of grant. and was fully vested and exercisable. In accordance with the Business Combination Agreement, each stock option of Praxair outstanding immediately prior to the effective date of the Business Combination (whether vested or unvested) was automatically converted into an option to purchase shares of Linde plc ordinary shares equal to the total number of shares of Praxair Common Stock subject to such option immediately prior to the closing of the Business Combination and at a per-share exercise price equal to the per-share exercise price of Praxair's option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.80 · Expires 2024-02-25 | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-10-31 · Disposition to issuer · Disposed 3,735 · Balance 0 F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. F5: This option became exercisable in three (3) equal annual installments beginning on the first anniversary of the date of grant. and was fully vested and exercisable. In accordance with the Business Combination Agreement, each stock option of Praxair outstanding immediately prior to the effective date of the Business Combination (whether vested or unvested) was automatically converted into an option to purchase shares of Linde plc ordinary shares equal to the total number of shares of Praxair Common Stock subject to such option immediately prior to the closing of the Business Combination and at a per-share exercise price equal to the per-share exercise price of Praxair's option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.38 · Expires 2025-02-24 | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-10-31 · Disposition to issuer · Disposed 5,150 · Balance 0 F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. F5: This option became exercisable in three (3) equal annual installments beginning on the first anniversary of the date of grant. and was fully vested and exercisable. In accordance with the Business Combination Agreement, each stock option of Praxair outstanding immediately prior to the effective date of the Business Combination (whether vested or unvested) was automatically converted into an option to purchase shares of Linde plc ordinary shares equal to the total number of shares of Praxair Common Stock subject to such option immediately prior to the closing of the Business Combination and at a per-share exercise price equal to the per-share exercise price of Praxair's option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.22 · Expires 2026-02-23 | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-10-31 · Disposition to issuer · Disposed 9,360 · Balance 0 F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. F6: This options vests over three years in three consecutive equal annual installments beginning on February 23, 2017. In accordance with the Buiness Combination Agreement , each stock option of Praxair outstanding immediately prior to the effective date of the Business Combination (whether vested or unvested) was automatically converted into an option to purchase shares of Linde plc ordinary shares equal to the total number of shares of Praxair Common Stock subject to such option immediately prior to the closing of the Business Combination and at a per-share exercise price equal to the per-share exercise price of Praxair's option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $118.71 · Expires 2027-02-28 | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-10-31 · Disposition to issuer · Disposed 10,500 · Balance 0 F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. F7: This option vests over three years in three consecutive equal annual installments beginning on February 28, 2018. In accordance with the Business Combination Agreement, each stock option of Praxair outstanding immediately prior to the effective date of the Business Combination (whether vested or unvested) was automatically converted into an option to purchase shares of Linde plc ordinary shares equal to the total number of shares of Praxair Common Stock subject to such option immediately prior to the closing of the Business Combination and at a per-share exercise price equal to the per-share exercise price of Praxair's option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $154.00 · Expires 2028-02-27 | Direct | 0 |
Reported balance
After 2018-10-31 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-10-31 · Disposition to issuer · Disposed 9,700 · Balance 0 F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc. F8: This option vests over three years in three consecutive equal annual installments beginning on February 27, 2019. In accordance with the Business Combination Agreement, each stock option of Praxair outstanding immediately prior to the effective date of the Business Combination (whether vested or unvested) was automatically converted into an option to purchase shares of Linde plc ordinary shares equal to the total number of shares of Praxair Common Stock subject to such option immediately prior to the closing of the Business Combination and at a per-share exercise price equal to the per-share exercise price of Praxair's option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of Praxair common stock in connection with the consummation of the transactions contemplated by the Business Combination Agreement (the "BCA") dated as of June 1, 2017, by and among Linde Aktiengesellschaft, Praxair, Inc., a Delaware corporation (the "Company"), Linde plc, Zamalight Holdco LLC, and Zamalight Subco, Inc. (the "Business Combination"). In connection with the Business Combination, Praxair, Inc. became an indirect wholly-owned subsidiary of Linde plc, and each share of Praxair common stock, par value $0.01 per share, was exchanged for one Ordinary Share of Linde plc.
F2: Restricted Stock Units ("RSUs") that were previously awarded by Praxair, Inc. will vest 100% on February 27, 2021. In connection with the BCA, the RSUs have been converted into RSUs of Linde plc Ordinary Shares on a one-for-one basis.
F3: Restricted Stock Units previously awarded by Praxair on February 23, 2016 that will vest and payout on February 23, 2019. In connection with the BCA, the RSUs were converted to RSUs of Linde plc Ordinary Shares on a one-for-one basis.
F4: Restricted Stock Units previously awarded by Praxair, Inc. on February 28, 2017 that will vest and payout on February 28, 2020. In connection with the BCA, the RSUs were converted to RSUs of Linde plc Ordinary Shares on a one-for-one basis.
F5: This option became exercisable in three (3) equal annual installments beginning on the first anniversary of the date of grant. and was fully vested and exercisable. In accordance with the Business Combination Agreement, each stock option of Praxair outstanding immediately prior to the effective date of the Business Combination (whether vested or unvested) was automatically converted into an option to purchase shares of Linde plc ordinary shares equal to the total number of shares of Praxair Common Stock subject to such option immediately prior to the closing of the Business Combination and at a per-share exercise price equal to the per-share exercise price of Praxair's option.
F6: This options vests over three years in three consecutive equal annual installments beginning on February 23, 2017. In accordance with the Buiness Combination Agreement , each stock option of Praxair outstanding immediately prior to the effective date of the Business Combination (whether vested or unvested) was automatically converted into an option to purchase shares of Linde plc ordinary shares equal to the total number of shares of Praxair Common Stock subject to such option immediately prior to the closing of the Business Combination and at a per-share exercise price equal to the per-share exercise price of Praxair's option.
F7: This option vests over three years in three consecutive equal annual installments beginning on February 28, 2018. In accordance with the Business Combination Agreement, each stock option of Praxair outstanding immediately prior to the effective date of the Business Combination (whether vested or unvested) was automatically converted into an option to purchase shares of Linde plc ordinary shares equal to the total number of shares of Praxair Common Stock subject to such option immediately prior to the closing of the Business Combination and at a per-share exercise price equal to the per-share exercise price of Praxair's option.
F8: This option vests over three years in three consecutive equal annual installments beginning on February 27, 2019. In accordance with the Business Combination Agreement, each stock option of Praxair outstanding immediately prior to the effective date of the Business Combination (whether vested or unvested) was automatically converted into an option to purchase shares of Linde plc ordinary shares equal to the total number of shares of Praxair Common Stock subject to such option immediately prior to the closing of the Business Combination and at a per-share exercise price equal to the per-share exercise price of Praxair's option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2017 Filed Mar 1, 2017 22:44 UTC | PRAXAIR INC PX · Entity 162268 | Tax withholdingCommon Stock | 81 | $118.11 | $9,566.91 |
DisclosureSEC source: 0000884905-17-000012 · edgar.xml · nonDerivative · entry 3 Hoyt Kelcey E · CIK 0001681090 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307 F2 · shares: Shares of common stock withheld from the PSU payout to cover tax withholdings. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:44 UTC | PRAXAIR INC PX · Entity 162268 | Exercise / conversionCommon Stock | 240 | $0.00 | $0.00 |
DisclosureSEC source: 0000884905-17-000012 · edgar.xml · nonDerivative · entry 2 Hoyt Kelcey E · CIK 0001681090 · Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock acquired pursuant to the payout of a performance share unit grant made on February 25, 2014 (the "PSU"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.